Sunday, July 6, 2025 7/6/2025

CHEMOPREVENTION OF COLITIS-ASSOCIATED NEOPLASIA BY 5-ASA

Award Number: R01CA124693
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2008
PERIOD OF PERFORMANCE END DATE: 05/31/2013

Group Awards By:

View Award Description

CHEMOPREVENTION OF COLITIS-ASSOCIATED NEOPLASIA BY 5-ASA - DESCRIPTION (provided by applicant): Although ulcerative colitis patients are at a significantly increased risk of developing colorectal cancer as compared to the general population, little attention has been given to the development of a chemopreventive intervention for this high-risk population. Furthermore, colonoscopies fail to reliably detect early lesions, in particular flat dysplasias, in ulcerative colitis patients. Rationale for the proposed study is provided by preliminary data from this group that demonstrate the ability of 5-aminosalicylic acid (5-ASA), the first-line therapy for the treatment of human colitis, to inhibit the multiplicity of AOM/DSS-induced colitis-associated dysplasias in mice when given prior to the induction of colitis. Most interesting was the potential differential response of polypoid (reduction in size) and flat (decrease in multiplicity) dysplasias to drug therapy. These data suggest that flat and polypoid dysplasias may respond differently to 5-ASA exposure and that these lesion subtypes may arise via independent genetic pathways. More recent data from this group confirm that 5-ASA can inhibit colitis-associated lesions when administered after the induction of DSS; a schedule of clinical relevance. The overall goal of this study is to gain new insight into the chemopreventive activity of 5-ASA against AOM/DSS-induced colitis-associated colorectal cancer by combining novel imaging techniques with state- of-the-art advances in genetic profiling and bioinformatics. The hypothesis of the proposed experimentation is that 5-ASA effectively inhibits colitis-associated neoplasia by altering the growth of polypoid and flat lesions via distinct genetic pathways. The ability of an optimal dose of 5-ASA to decrease the multiplicity and size of colonic dyplasias as well as associated inflammation will be examined in Specific Aim 1. These data will be complemented by the use of MRI, colonoscopy and whole-body fluorescence imaging with biologically activated probes to monitor both the degree of inflammation (colon wall thickness) and the growth of polypoid and flat lesions over time. In Specific Aim 3, microarray-based analyses will be employed to compare and contrast the gene expression profile of inflamed nonneoplastic mucosa with that of polypoid and flat dysplasias as well as to identify those genes whose expression is altered in each tissue type following exposure to 5-ASA. Findings from these preclinical analyses are anticipated to enhance our understanding of the genetic basis of polypoid and flat colitis-associated dysplasias and facilitate the development of a chemopreventive regimen for ulcerative colitis patients at increased risk for colonic malignancies. PUBLIC HEALTH RELEVANCE: Because colonoscopies do not reliably detect early colon cancer in ulcerative colitis patients, there is a great need to develop a cancer preventive therapy for this high-risk population. Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $359,108 )
2012	2012	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Cause and Prevention Research	001	5	5/25/2012	NON-COMPETING CONTINUATION	$359,108
2012	2009	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	000	2	10/18/2011	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $359,108

Issue Date FY: 2011 ( Subtotal = $351,225 )
2011	2011	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Cause and Prevention Research	000	4	5/20/2011	NON-COMPETING CONTINUATION	$351,225
2011	2009	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	001	2	6/21/2011	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $351,225

Issue Date FY: 2010 ( Subtotal = $362,088 )
2010	2010	FOX CHASE CANCER CENTER	7701 BURHOLME AVENUE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Cause and Prevention Research	000	3	5/26/2010	NON-COMPETING CONTINUATION	$362,088
														Subtotal = $362,088

Issue Date FY: 2009 ( Subtotal = $1,375,008 )
2009	2009	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	001	2	9/18/2009	SUPPLEMENT FOR EXPANSION	$664,093
2009	2009	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Cancer Cause and Prevention Research	000	2	6/2/2009	NON-COMPETING CONTINUATION	$361,915
2009	2009	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Trans-NIH Recovery Act Research Support	002	2	9/29/2009	SUPPLEMENT FOR EXPANSION	$349,000
														Subtotal = $1,375,008

Issue Date FY: 2008 ( Subtotal = $360,013 )
2008	2008	FOX CHASE CANCER CENTER	7701 BURHOLME AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Cause and Prevention Research	000	1	6/6/2008	NEW	$360,013
														Subtotal = $360,013

Grand Total All Awards = $2,807,442

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CHEMOPREVENTION OF COLITIS-ASSOCIATED NEOPLASIA BY 5-ASA

Award Number: R01CA124693

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2008

PERIOD OF PERFORMANCE END DATE: 05/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer